In the medical field, terminology not only guides clinical understanding and patient communication but also impacts research, ...

Many companies in the biotech industry performed well last year. Two in particular stood out: Viking Therapeutics (NASDAQ: ...

Nonalcoholic steatohepatitis (NASH) is the progressive form of liver injury that carries a risk for progressive fibrosis, cirrhosis, and end-stage liver disease. Hepatocellular carcinoma (HCC ...

These organizations can help you educate yourself, spread awareness, and connect with the MASH community to help you better ...

Fintel reports that on February 7, 2025, Citigroup initiated coverage of Viking Therapeutics (NasdaqCM:VKTX) with a Neutral ...

As the CEO of Karyon Bio, Thirunagari introduced the company’s ground breaking Digital Liver initiative, an AI-powered ...

† NASHTest is a combination of age, gender, height, weight serum triglycerides, cholesterol, α2-macroglobulin, apolipoprotein A1, haptoglobin, γ ...

If you have diabetes, taking steps to manage it can help prevent related health issues, including MASH. Here’s what to know ...

gmx.net Objective Monocyte chemoattractant protein-1 (MCP-1, CCL2), the primary ligand for chemokine receptor C–C chemokine receptor 2 (CCR2), is increased in livers of patients with non-alcoholic ...

HC Wainwright restated their buy rating on shares of Altimmune (NASDAQ:ALT – Free Report) in a research report report published on Wednesday,Benzinga reports. The firm currently has a $12.00 price ...

For patients with compensated metabolic dysfunction-associated steatohepatitis (MASH)-related cirrhosis and obesity, ...